Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

Katharine Patrick, Rachel Wade, Nicholas Goulden, Clare Rowntree, Rachael Hough, Anthony V. Moorman, Christopher D. Mitchell, Ajay Vora

Research output: Contribution to journalArticle

Abstract

We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.

Original languageEnglish (US)
Pages (from-to)552-555
Number of pages4
JournalBritish journal of haematology
Volume165
Issue number4
DOIs
StatePublished - May 2014

Keywords

  • Down syndrome
  • Lymphoblastic leukaemia
  • Treatment

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol'. Together they form a unique fingerprint.

  • Cite this